Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390115 | 0.86 | RET (0.39) | RETDRD2DRD4CHRM4CYP3A4 | |
| SCHEMBL17531283 | 0.85 | CYP3A4 (0.40) | RETDRD2DRD4CHRM4CYP3A4 | |
| SCHEMBL20328006 | 0.83 | TRPA1 (0.36) | RETDRD2DRD4CHRM4CYP3A4 | |
| SCHEMBL20353623 | 0.82 | TRPA1 (0.37) | RETDRD2DRD4CHRM4CYP3A4 | |
| SCHEMBL29516567 | 0.80 | CYP3A4 (0.36) | RETDRD2DRD4CYP3A4CYP2C19 | |
| SCHEMBL19199138 | 0.76 | CYP3A4 (0.46) | DRD2DRD4CHRM4CYP3A4CYP2C19 | |
| SCHEMBL20148017 | 0.72 | SMN1; SMN2 (0.43) | RETCYP3A4LMNAHPGDSMN1; SMN2 | |
| SCHEMBL20069764 | 0.70 | JAK2 (0.42) | RETDRD2DRD4CHRM4LMNA | |
| SCHEMBL18390143 | 0.69 | RET (0.41) | RETDRD2DRD4 | |
| SCHEMBL17340074 | 0.68 | DGAT1 (0.34) | CYP3A4CYP2C19LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885DRD2 2385/4885DRD4 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.